Hemodynamic and Perfusion Response to Drotrecogin Alfa (Activated) in Patients With Septic Shock

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

43 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-11-30

Study Completion Date

2007-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study will evaluate the vasopressor requirement, hemodynamic response and measures of tissue perfusion in patients with septic shock receiving an infusion of drotrecogin alfa (activated) compared to patients not receiving drotrecogin alfa (activated).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock

NCT00604214

Sepsis

COMPLETED PHASE3

The Study of Drotrecogin Alfa (Activated) in Adult Patients With Severe Sepsis at a Low Risk of Death

NCT00568737

Sepsis

COMPLETED PHASE3

The Study of Drotrecogin Alfa (Activated) in a Subpopulation of Adult Patients With Severe Sepsis

NCT00045760

Sepsis

COMPLETED PHASE4

Evaluate Protein C Levels in Severe Sepsis Patients on Drotrecogin Alfa (Activated)

NCT00386425

Severe Sepsis

COMPLETED PHASE2

An Open Label Study of Severe Sepsis in Adults

NCT00568893

Severe Sepsis

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sepsis Septic Shock

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

drotrecogin alfa (activated)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years of age or older with a diagnosis of septic shock
* presence of a pulmonary artery catheter (or central venous catheters)
* requiring vasopressor support despite adequate fluid resuscitation
* an intravenous steroid administered for septic shock, except for those patients who were tested and are responders to a corticotropin stimulation test, or patients who do not receive a steroid due to the clinical judgment of the treating physician, based on an alternate assessment (e.g. normal baseline cortisol).

Exclusion:

* Onset of first-sepsis induced organ dysfunction is greater than 24 hours from the time of informed consent
* Baseline measurements of pulmonary artery occlusive pressure (PAOP) \< 12 mmHg or a central venous pressure (CVP) \< 8 mmHg
* Patient requires continuous oxygen therapy by face-mask
* The presence of an advanced directive to withhold life-sustaining treatment, with the exception of a directive to withhold chest compressions only
* Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry
* Weight \> 200 kg
* Are moribund (not expected to survive 24 hours)
* Are pregnant or are lactating and the milk is to be ingested by the infant (pregnancy status must be verified by urine or serum testing)
* Have not completed written informed consent signed by the patient or the patient's legal representative.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No